【摘要】 目的:观察紫杉醇、奥沙利铂联合榄香烯腹腔灌注治疗胃癌晚期癌性腹水的疗效和安全性。方法:52例胃癌晚期癌性腹水患者随机分为对照组（26例）和观察组（26例）。对照组患者取仰卧位,腹腔穿刺成功后将软管置于腹腔内,先抽取腹水1 000¹ 500ml,后腹腔灌注紫杉醇注射液120 mg/m2,d₁+注射用奥沙利铂85 mg/m2,d₁;观察组患者在对照组治疗的基础上腹腔灌注榄香烯注射液0.5 g+2%盐酸利多卡因注射液0.2 g。两组均以14 d为1个周期,治疗至患者死亡或疗程达到1年。观察两组患者的近期临床疗效、临床获益率、1年生存率、死亡患者中位生存期及毒性反应发生情况。结果:观察组患者总有效率、临床获益率、1年生存率均显著高于对照组,死亡患者中位生存期显著长于对照组,差异均有统计学意义（P<0.05）。两组患者毒性反应发生率比较差异无统计学意义（P>0.05）。结论:紫杉醇、奥沙利铂联合榄香烯腹腔灌注治疗胃癌晚期癌性腹水的疗效和安全性均较好。更多还原

【Abstract】 OBJECTIVE:To observe the efficacy and safety of paclitaxel,oxaliplatin combined with elemene by peritoneal perfusion in the treatment of advanced gastric cancer with ascites. METHODS:52 patients with advanced gastric cancer with ascites were randomly divided into control group（26 cases）and observation group（26 cases）. Patients in control group were in supine position,tube was placed in the abdominal cavity after peritoneal puncture,releasing ascites 1 000-1 500 ml,then Paclitaxel injection120 mg/m² was used by peritoneal perfusion,d₁+Oxaliplatin for injection 85 mg/m²,d₁. Patients in observation group were additionally given Elemene injection 0.5 g by peritoneal perfusion+2% lidocaine hydrochloride injection 0.2 g. 14 d was a treatment course,patients were treated to death or a course of 1 year. Clinical efficacy,clinical benefit rate,1-year survival rate,median survival time of death patients and the incidence of toxicities in 2 groups were observed. RESULTS:The total effective rate,clinical benefit rate and 1-year survival rate in observation group were significantly higher than control group,median survival time of death patients was significantly longer than control group,with statistical significance（P<0.05）. And there was no significant difference in the incidence of toxicities in 2 groups（P>0.05）. CONCLUSIONS:Paclitaxel,oxaliplatin combined with elemene by peritoneal perfusion has both good efficacy and safety in the treatment of advanced gastric cancer with ascites.更多还原